For anyone fogged-up with these decisive and overarching statements about Leronlimab's statistical demise that is arrived at through magical mathematical and research expertise and applied from such a distant lens from the work and patients and yet with the precision of a neurosurgeon - you may want to consider the following to anchor yourself back to reality...
How would a world-class maven ignore:
HIV viral load reduction to below measurable levels, as proven in-vivo in hundreds of patients and for some over multiple years, while considering whether the drug has any biological effect?
The immune system biomarkers modulated and brought under control by the application of Leronlimab - as measured consistently and repeatedly in patients receiving the biologic, while considering whether the drug has any biological effect??
The fact that CCR5 inhibition is cited in hundreds of scientific papers and ACCEPTED globally as a key target for immune disorders, cancer and infectious diseases - WHILE having an approved drug in the class and having unquestionable proof that Leronlimab reaches 100% receptor occupancy in proven and repeatable experiments, while considering whether the drug has any biological effect?
That the FDA is STILL allowing Expanded Access and Open Label access to the drug for COVID as well as Expanded Access for certain cancers, while considering whether the drug has any biological effect?
That hospitals across the US are administering Leronlimab to their patients IN THE PRESENT, while considering whether the drug has any biological effect?
That perhaps hundreds of independent physicians and researchers voiced support for the MOA and drug itself across the US and several countries outside its borders, while considering whether the drug has any biological effect?
That the Philippines medical community and government administered this drug to its ex-president and then expanded access to the drug within its hospital systems, while considering whether the drug has any biological effect?
That patients are receiving the drug in a cancer basket trial IN THE PRESENT, while considering whether the drug has any biological effect?
There are so many more...
Ask yourself - Would a World-Class Maven:
Ignore the probability that the likelihood of all the above occuring by chance (as in not meeting the statistical significance p-value threshold of 0.05) is as close to zero as anything can ever get?
Believe the entire network of institutions, scientists, physicians, business associates, governments and other players is being hoodwinked and missing the obvious 'correct' answer that is only visible to said skilled maven?
Miss assessing the relevance between clinical significance, biomarker-level proof of effect and cross-correlative outcomes relevance between various treated conditions and instead revert to a p-value of an underpowered trial as the only indicator of efficacy?
Who's never touched a patient or seen one recover from COVID after failing multiple treatments and being at death's door have more credibility than said patient or their doctor?
Should a world-class maven with an interest in gaining from a stock's devaluation through shorting ever be considered an objectively reliable, balanced and honest source of investment input on said stock???
The answers to the above should be fairly obvious and dealt-with accordingly. If it doesn't pass the smell test then consider it a feeble attempt at entertainment and devote your attention to sources of information, pro and con CytoDyn, that can pass the real-world logic-test any infant (or first year college student) can apply when assessing options and actions.
Here's some potential events with outcomes that carry a reasonably high probability:
Results from a appropriately powered and successful trials will shift the stock's value to a completely different baseline
Upon that outcome - most of the gifted and helpful crowd will disappear into the quantum cracks of the internet faster than a photon in space
After reaching a new and higher trading baseline - a new, more capable and sophisticated gifted and helpful crowd, will appear to 'help' investors in supporting their journey to the next level
Market Data 
Markets 
AI
